Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All metformin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMetforminMetformin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 76% Improvement Relative Risk Metformin for COVID-19  Li et al.  LATE TREATMENT Is late treatment with metformin beneficial for COVID-19? Retrospective 131 patients in China Lower mortality with metformin (p=0.022) c19early.org Li et al., Endocrinology, Diabetes & M.., Sep 2021 Favors metformin Favors control

Inpatient use of metformin and acarbose is associated with reduced mortality of COVID-19 patients with type 2 diabetes mellitus

Li et al., Endocrinology, Diabetes & Metabolism, doi:10.1002/edm2.301
Sep 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Metformin for COVID-19
3rd treatment shown to reduce risk in July 2020
 
*, now known with p < 0.00000000001 from 88 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
Retrospective 131 hospitalized COVID-19 patients with type 2 diabetes, showing lower mortality with metformin treatment and acarbose treatment.
risk of death, 75.8% lower, RR 0.24, p = 0.02, treatment 2 of 37 (5.4%), control 21 of 94 (22.3%), NNT 5.9.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Li et al., 29 Sep 2021, retrospective, China, peer-reviewed, 13 authors. Contact: nianxiong@hust.edu.cn, wxli@health.ucsd.edu.
This PaperMetforminAll
Inpatient use of metformin and acarbose is associated with reduced mortality of COVID‐19 patients with type 2 diabetes mellitus
Jinghong Li, Qi Wei, Karen C Mccowen, Wei Xiong, Jiao Liu, Wenlijun Jiang, Robert L Thomas, Mark Hepokoski, Ming He, John Y J Shyy, Atul Malhotra, Nian Xiong, Willis X Li
Endocrinology, Diabetes & Metabolism, doi:10.1002/edm2.301
This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
DATA AVA I L A B I L I T Y S TAT E M E N T The data that support the findings of this study are available upon request from the lead author, J.L. O RCI D Willis X. Li https://orcid.org/0000-0001-9041-7341 R E FE R E N C E S
References
Beigel, Tomashek, Dodd, Remdesivir for the treatment of covid-19-final report, N Engl J Med
Bergmark, Bhatt, Mcguire, Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial, Circulation
Berlin, Gulick, Martinez, Severe covid-19, N Engl J Med
Clement, Braithwaite, Magee, Management of diabetes and hyperglycemia in hospitals, Diabetes Care
Gabir, Hanson, Dabelea, Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American diabetes association and 1999 world health organization criteria for diagnosis of diabetes, Diabetes Care
Geleris, Sun, Platt, Observational study of hydroxychloroquine in hospitalized patients with covid-19, N Engl J Med
Gu, Shi, Tang, Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a metaanalysis, PLoS One
Gu, Wang, Li, Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment, Nat Commun
Hanefeld, The role of acarbose in the treatment of noninsulin-dependent diabetes mellitus, J Diabetes Complications
Horby, Lim, Emberson, Dexamethasone in hospitalized patients with covid-19-preliminary report, N Engl J Med
Jarcho, Ingelfinger, Hamel, Agostino, Harrington, Inhibitors of the renin-angiotensin-aldosterone system and covid-19, N Engl J Med
Jia, Weng, Zhu, Standards of medical care for type 2 diabetes in China 2019, Diabetes Metab Res Rev
Kavanagh, Mccowen, Clinical practice. glycemic control in the ICU, N Engl J Med
Li, Wei, Li, Metformin use in diabetes prior to hospitalization: effects on mortality in covid-19, Endocr Pract
Malhotra, Hepokoski, Mccowen, Shyy, Metformin, and COVID-19, iScience, doi:10.1016/j.isci.2020.101425
Malhotra, Intensive insulin in intensive care, N Engl J Med
Mo, Liu, Ma, Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study, Drug Des Devel Ther
Rosas, Bräu, Waters, Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia, N Engl J Med
Rosenberg, Dufort, Udo, Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State, JAMA
Salama, Han, Yau, Tocilizumab in patients hospitalized with Covid-19 pneumonia, N Engl J Med
Stone, Frigault, Boyd, Efficacy of tocilizumab in patients hospitalized with covid-19, N Engl J Med
Venter, Richter, Towards effective diagnostic assays for COVID-19: a review, J Clin Pathol
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet
Wu, Chen, Cai, Risk Factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med
Xu, Han, Li, Effective treatment of severe COVID-19 patients with tocilizumab, Proc Natl Acad Sci U S A
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit